reports
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
Achieve Life Sciences Announced Granting of New Hire Inducement Awards SEATTLE and VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced that the company has issued inducement grants of stock options to Erik Atkisson, Chief Legal Officer, and other new employees. As an inducement to employment, Achieve’s Board of Directors granted Mr. Atkisson options to purchase u...
Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Pr...
Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Vaping CessationConference Call Scheduled for 8:30 AM EST Today, November 6, 2025 SEATTLE and VANCOUVER, British Columbia, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today ann...
Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA...
Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation 120-Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully ConcludedDSMC Completes Final Review of Cytisinicline, Finds No Drug Safety Concerns SEATTLE and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced several milestones in its ORCA-OL long...
Achieve Life Sciences to Announce Third Quarter Financial Results and ...
Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025 SEATTLE and VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its third quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Thursday, November 6, 2025...
Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer
Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companies SEATTLE and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced the appointment of Erik Atkisson as Chief Legal Officer. In his new ro...
Achieve Life Sciences Receives FDA Commissioner's National Priority Vo...
Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation Potential First-in-Class Treatment for Nicotine E-cigarette or Vaping Cessation Receives Unprecedented Expedited Review Pathway One of Only Nine Therapies Chosen for the FDA’s Inaugural National Priority Voucher Program SEATTLE and VANCOUVER, British Columbia, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and com...
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
Achieve Life Sciences Announces Granting of New Hire Inducement Awards SEATTLE and VANCOUVER, British Columbia, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced that effective October 1, 2025, Achieve’s board of directors approved stock option grants to purchase an aggregate of 161,000 shares of its common stock for five new employees under Achieve’s 2024 Equity Induce...
Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Offi...
Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer Donnelly brings more than 25 years of biopharmaceutical expertise in CMC and regulatory operations SEATTLE and VANCOUVER, British Columbia, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced the promotion of Craig Donnelly to Chief Operations Officer. Mr. Donnelly has been with Achieve since 2...
Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical ...
Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced Mark Rubinstein, M.D., will assume the role of Interim Chief Medical Officer (CMO). Dr. Rubinstein will succeed Cindy Jacobs, Ph.D., M.D., who we anticipate will provide advisory services to support the...
Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Dr...
Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation Filing based on pivotal Phase 3 ORCA-2 and ORCA-3 clinical trials demonstrating statistically significant and clinically meaningful smoking cessation FDA acceptance starts the review process and sets timing for potentially the first new FDA-approved pharmacotherapy in two decadesPDUFA targeted date set for June 20, 2026 SEATTLE and VANCOUVER, British Columbia, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a ...
Achieve Life Sciences Announces Participation at Upcoming Investor Con...
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences SEATTLE and VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that Rick Stewart, CEO of Achieve Life Sciences, will be participating at two upcoming conferences. Details are as follows: H.C. Wainwright 27th Annual Global Investment ConferenceDate: Monday, Septe...
Achieve Life Sciences Reports Second Quarter 2025 Financial Results; P...
Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program Conference Call Scheduled for 8:30 AM EDT Today, August 7, 2025 SEATTLE and VANCOUVER, British Columbia, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for second quarter 2025. “This quarter represents a significant step forward f...
Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology...
Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference SEATTLE and VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that the company will participate in the BTIG Virtual Biotechnology Conference being held July 29-30, 2025. Rick Stewart, Chief Executive Officer of Achieve, will participate in a fireside chat wit...
Achieve Life Sciences to Announce Second Quarter Financial Results and...
Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025 SEATTLE and VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its second quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Thursday, August 7, 2025, ...
Achieve Life Sciences Announces Closing of Public Offering of Common S...
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters’ Option to Purchase Additional Securities SEATTLE and VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced the closing of its underwritten public offering of 15,000,000 shares of its common stock and accompanying common warrants to p...
Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten ...
Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock and accompanying common warrants to purchase up to 15,000,000 shares of common stock. The shares of common...
Achieve Life Sciences Announces Proposed Underwritten Public Offering
Achieve Life Sciences Announces Proposed Underwritten Public Offering SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to pu...
Achieve Life Sciences Announces Partnership with Omnicom to Execute In...
Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades Omnicom cross-agency collaboration to drive technology-led, innovative launch strategy Partnership brings together promising science, top-tier talent, and advanced technologies to enable a faster, smarter, and more effective path to address a critical public health need SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialt...
Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinic...
Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation Smoking, the leading cause of preventable death and disease, continues to affect nearly 29 million adults in the U.S. alone If approved, cytisinicline will be the first new FDA-approved pharmacotherapy option for nicotine dependence in two decades More than 2,000 clinical trial participants contributed to the body of evidence submitted in the NDA demonstrating cytisinicline’s efficacy, safety, and tolerability profile SEATTLE and VANCOUVER, British Colum...
Achieve Life Sciences to Present at the Jefferies Global Healthcare Co...
Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference SEATTLE and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that the company will present at the Jefferies Global Healthcare Conference being held June 3–5, 2025, in New York City. Rick Stewart, Chief Executive Officer of Achieve, will present on Wednesday, Jun...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.